FDA 483 - Cipla, Ltd. - March 20, 2019

This FDA Form 483 report details significant deficiencies at Cipla Ltd., a manufacturer of Active Pharmaceutical Ingredients and finished drug products. Observations highlight an ineffective quality management system, inadequate investigations, insufficient employee training, and a lack of process validation and control for critical manufacturing processes. The findings indicate a systemic failure to ensure product quality and consistency.